Deciphering the mechanism of aristolochic acid I-driven hepatocellular carcinoma through integrated network toxicology and bioinformatics
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04853-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Yuling Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong Province, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Aristolochic Acids, Liver Neoplasms, Carcinogens. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Major Innovation Technology Construction Project of Synergistic Chinese Medicine and Western Medicine of Guangzhou, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome、Science and Technology Planning Projiect of Guangdong Province.
Abstract (Originalsprache)
Aristolochic acid I (AAI) is a known liver carcinogen, but its molecular mechanisms in hepatocellular carcinoma (HCC) remain incompletely understood. This study aimed to systematically elucidate these mechanisms. This study employed a multidisciplinary strategy: assessing AAI carcinogenicity via ProTox-3.0; identifying its targets using PubChem; and screening HCC-related genes from GEO. Core genes were filtered through network toxicology and Lasso-Cox regression. Molecular docking and dynamics simulations analyzed AAI-protein interactions, while GO, KEGG, and GSEA enrichment revealed relevant pathways. Key gene expression and clinical relevance were validated via TCGA and HPA databases. The carcinogenic potential of the AAI was 0.77. Fifty-two potential targets of AAI-induced HCC were identified. Network toxicology analysis identified 12 core genes including EZH2, FABP5, and RXRA. Lasso-Cox regression analysis identified four core genes that drive HCC progression, including EZH2. Functional enrichment analysis revealed that AAI-HCC targets were significantly enriched in lipid metabolism and the PPAR signaling pathway (p < 0.05), with the PPAR signaling pathway being significantly activated in HCC. Molecular docking and MD simulations confirmed the high affinity and stable binding of AAI to EZH2, FABP5, and RXRA. Through in silico and database-based validation, biological samples and clinical data confirmed that these genes were significantly overexpressed in HCC (p < 0.001) and were correlated with poor prognosis (p < 0.01). AAI may synergistically activate the PPAR signaling pathway by targeting EZH2, FABP5, and RXRA, driving lipid metabolism reprogramming and promoting the occurrence and development of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong Province, China.
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510400, Guangdong Province, China.
- Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong Province, China. sunbaog@mail.sysu.edu.cn.
- Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong Province, China. zhshjun@mail.sysu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Major Innovation Technology Construction Project of Synergistic Chinese Medicine and Western Medicine of Guangzhou
- Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome、Science and Technology Planning Projiect of Guangdong Province
Zitieren
APA
Liang, Y., Ning, X., Chen, Q., Zhang, S., Luo, H., Yu, H., Li, T., Sun, B., & Zhang, S. (2025). Deciphering the mechanism of aristolochic acid I-driven hepatocellular carcinoma through integrated network toxicology and bioinformatics. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04853-x
Vancouver
Liang Y, Ning X, Chen Q, Zhang S, Luo H, Yu H, et al. Deciphering the mechanism of aristolochic acid I-driven hepatocellular carcinoma through integrated network toxicology and bioinformatics. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04853-x
BibTeX
@article{Liang2025,
author = {Liang, Yuling and Ning, Xing and Chen, Qiuxia and Zhang, Shuqiao and Luo, Huishan and Yu, He and Li, Tangjiaqi and Sun, Baoguo and Zhang, Shijun},
title = {Deciphering the mechanism of aristolochic acid I-driven hepatocellular carcinoma through integrated network toxicology and bioinformatics},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04853-x}
}
EUVIMED